Related Experiment Video
Updated: May 28, 2026

Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α
Published on: June 14, 2018
Artificial Intelligence Algorithm Based on Genetics to Predict Responses to Interferon-Beta Treatment in Multiple
Edgar Rafael Ponce de León-Sánchez1, Jorge Domingo Mendiola-Santibañez2, Omar Arturo Domínguez-Ramírez3
1Facultad de Informática, Universidad Autónoma de Querétaro, Querétaro 76230, Mexico.
Abstract:
Multiple sclerosis (MS) is an inflammatory disease of the central nervous system (CNS) that impacts nearly 3 million people worldwide. While the etiology and pathogenesis of MS are not yet fully understood, current evidence suggests that it results from complex interactions between genetic and environmental conditions. Clarifying the autoimmune mechanisms underlying MS remains a central objective in the development of effective therapeutic strategies. Interferon-beta (IFN-β) is one of the most frequently prescribed disease-modifying treatments for individuals with MS. However, despite its established efficacy, recent studies report that approximately 30-50% of patients exhibit inadequate response to IFN-β, largely due to genetic variability. Machine learning (ML), a branch of artificial intelligence (AI), employs data-driven computational models to enhance predictive accuracy and classification. In recent MS research, unsupervised learning techniques such as hierarchical clustering and K-means have been applied for classification purposes. However, these methods often fail to yield optimal solutions because they require numerous arbitrary decisions and perform adequately only when datasets contain clusters of similar sizes and lack significant outliers. Fuzzy systems (FSs) are designed to model complex, ambiguous real-world phenomena. In this study, an AI algorithm incorporating a fuzzy system, informed by expert neurologist input, is proposed to enhance the assignment of unknown class labels related to IFN-β response in MS patients. Additionally, a genetic algorithm (GA) is introduced to identify optimal solutions within the search space, facilitating hyperparameter optimization of a deep learning (DL) model trained with genetic biomarkers to identify patients likely to benefit from this therapy. Experimental results demonstrate that the fuzzy system achieved 80% classification efficiency, in contrast to 64% with conventional hierarchical clustering. Furthermore, an artificial neural network (ANN) model, with hyperparameters optimized by the GA, achieved an accuracy of 0.8-1.0, surpassing the multi-layer perceptron (MLP), which achieved 0.6-0.8 accuracy using conventional tuning methods.
